Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192259 | 1.00 | MAPT (0.31) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL26242572 | 0.85 | GPR84 (0.36) | — | |
| SCHEMBL469207 | 0.83 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL469194 | 0.83 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL10192262 | 0.83 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL16510115 | 0.82 | MAPT (0.33) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL26008095 | 0.80 | GPR119 (0.33) | — | |
| SCHEMBL19573452 | 0.78 | IDH1 (0.32) | — | |
| SCHEMBL13186805 | 0.78 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL13844342 | 0.78 | MAPT (0.32) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334898-A9 | NOVEL 4-METHYL-DIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334898-A9 | NOVEL 4-METHYL-DIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPMT, DPYD, HAVCR2 | MAPT 3835/4885CYP2C9 291/4885CYP2C19 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.